BR

Active Director Director DIN 01648336
DIN 01648336 First appointment Dec 1996 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Dec 1996
Shareholding value •••• Premium profile

About Bibek Roy

Data last updated:

Bibek Roy is a Director at Medeor Pharma Pvt Ltd (since 1996). The company operates in Pharma. Medeor Pharma Pvt Ltd reported revenue of ₹3.19 Cr (FY 2025).

DIN 01648336
Primary Designation Director
Industry Pharma
First Appointment 24 Dec 1996
Oldest Company Age 43 yrs
Largest company Medeor Pharma Pvt Ltd · ₹3.19 Cr (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Medeor Pharma Pvt Ltd U51909WB1983PTC035981
Director24 Dec 19961983₹3.19 Cr (FY 2025)Active

Board colleagues of Bibek Roy

NameDINCompanyDesignation
Arup Das01648310Medeor Pharma Pvt LtdDirector
Bratati Sinha Ray09317931Medeor Pharma Pvt LtdAdditional Director

Directorship timeline

Open interactive timeline →
Medeor Pharma Pvt Ltd
Premium access

Shareholding and investment profile for Bibek Roy

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Bibek Roy

Bibek Roy currently holds 1 directorship: Medeor Pharma Pvt Ltd (Director, since 24 Dec 1996, revenue ₹3.19 Cr (FY 2025)).

Bibek Roy was first appointed on 24 Dec 1996 as Director at Medeor Pharma Pvt Ltd.

The current boards of Bibek Roy's companies include Arup Das (Medeor Pharma Pvt Ltd), Bratati Sinha Ray (Medeor Pharma Pvt Ltd).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available